by Plasmid DNA manufacturing is a method for production of DNA that is used in gene therapy and DNA vaccines. Plasmid DNA is advantageous as it is easy to produce, stable at room temperature, and provides long term gene expression. There is a rising demand for plasmid DNA due to the increasing adoption of gene therapy for treatment of various diseases like cancer.
The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: The rising demand for gene therapy treatments is one of the major trends fueling the growth of the plasmid DNA manufacturing market. Gene therapy uses genes to treat or prevent diseases by delivering genetic material into cells. Plasmid DNA plays a key role in gene therapy as it encodes therapeutic genes. Many gene therapy clinical trials are ongoing for treatment of cancer, cardiovascular diseases, infectious diseases and others which is boosting the demand for plasmid DNA globally. This rising adoption of gene therapy will drive the plasmid DNA manufacturing market during the forecast period.
SWOT Analysis
Strength: Plasmid DNA manufacturing has wide applications in gene therapy, DNA vaccines, and immunotherapy which drives the market growth. The availability of recombinant DNA technology aids in plasmid DNA mass production and purification.
Weakness: High costs associated with plasmid DNA manufacturing is a major challenge. Regulatory compliance and other patent issues related to plasmid DNA products limit market expansion.
Opportunity: Rising R&D in gene therapy and DNA vaccines offer lucrative opportunities. Increased collaborations between academic institutions and industry players can help address challenges and lower production costs.
Threats: Stringent regulations delay product approvals. Ethical issues related to gene therapy and safety concerns of plasmid DNA products pose threats.
Key Takeaways
The global Plasmid DNA Manufacturing market is expected to witness high growth. Global Plasmid DNA Manufacturing Market Size is estimated to be valued at US$ 901.2 Bn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
North America dominates currently due to strong government support and presence of major players. Asia Pacific is poised to grow at the fastest pace during the forecast period driven by increasing government funding for life science research.
Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc. Plasmid DNA manufacturing requires robust production processes and quality control measures. Leaders are focusing on expanding manufacturing capabilities and capacities to cater to the growing demand.
Collaborations between technology providers and end-users can help address current challenges. Continuous technological advancements in plasmid DNA production and purification technologies will likely boost market revenues. However, high costs and regulatory compliance remain major bottlenecks to broad market expansion.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
